Hydroxypropyl Cellulose
drugOn this page
Also known as E463Lacrisert
Summary
Hydroxypropyl Cellulose (CHEMBL1201471) is an approved unknown; indicated across 1 condition including keratoconjunctivitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201471 |
| Name | Hydroxypropyl Cellulose |
| Type | Unknown |
| Max phase | 4 |
Also known as: E463, Hydroxypropyl cellulose, Lacrisert, HYDROXYPROPYL CELLULOSE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| keratoconjunctivitis | 4 | MONDO:0004768 | MONDO:0004768 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: keratoconjunctivitis